uniQure (NASDAQ:QURE) CEO Matthew Kapusta Sells 21,082 Shares

uniQure N.V. (NASDAQ:QURE) CEO Matthew Kapusta sold 21,082 shares of uniQure stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $45.16, for a total transaction of $952,063.12. Following the sale, the chief executive officer owned 519,227 shares of the company’s stock, valued at approximately $23,448,291.32. The trade was a 3.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Price Performance

Shares of NASDAQ:QURE opened at $41.41 on Wednesday. The company’s fifty day moving average price is $31.47 and its 200-day moving average price is $24.15. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The firm has a market capitalization of $2.61 billion, a price-to-earnings ratio of -11.90 and a beta of 0.90. uniQure N.V. has a one year low of $8.73 and a one year high of $71.50.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.03. The company had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. On average, equities research analysts anticipate that uniQure N.V. will post -3.56 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Stifel Nicolaus set a $28.00 target price on uniQure in a research report on Tuesday, May 5th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of uniQure in a research note on Friday, June 26th. Mizuho increased their price target on shares of uniQure from $35.00 to $68.00 and gave the company an “outperform” rating in a research report on Thursday, June 25th. Finally, Cantor Fitzgerald raised shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target on the stock in a research note on Wednesday, June 17th. Twelve equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $64.17.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in QURE. Aberdeen Group plc raised its stake in shares of uniQure by 25.1% during the fourth quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock valued at $88,030,000 after acquiring an additional 738,897 shares during the last quarter. Quinn Opportunity Partners LLC purchased a new stake in shares of uniQure during the third quarter worth about $6,281,000. Farallon Capital Management LLC grew its stake in shares of uniQure by 3,935.7% in the third quarter. Farallon Capital Management LLC now owns 565,000 shares of the biotechnology company’s stock worth $32,979,000 after purchasing an additional 551,000 shares during the last quarter. Boone Capital Management LLC purchased a new position in uniQure during the 3rd quarter valued at about $8,599,000. Finally, Darwin Global Management Ltd. purchased a new position in uniQure during the 3rd quarter valued at about $23,760,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.